Trophos Blueprints Path To Exit With Actelion Option Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Trophos' deal with Actelion provides validation for the biotech's approach to rare disease R&D and lines up a solid exit for Trophos' venture backers - if Phase III data lives up to expectations.
You may also be interested in...
Actelion Passes On Trophos Acquisition After Failed Lou Gehrig's Study
Actelion decides not to exercise its option to acquire the Marseille-based French biotech Trophos after the failure of that company's lead compound, olesoxime, in a Phase III study in amyotrophic lateral sclerosis
Actelion Hedge-Fund Shareholder Urges Sale
Hedge fund Elliott Advisors calls for Actelion CEO to quit the board, declaring a sale of the group to be in shareholders' best interests
Actelion Hedge-Fund Shareholder Urges Sale
Hedge fund Elliott Advisors calls for Actelion CEO to quit the board, declaring a sale of the group to be in shareholders' best interests